873056-29-2

Basic information

• Product Name: 5-amino-2-(tert-butyl)benzonitrile
• Synonyms: 5-amino-2-(tert-butyl)benzonitrile
• CAS NO: 873056-29-2
• Molecular Weight: 174.246
• Mol File: 873056-29-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-amino-2-(tert-butyl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-2-(tert-butyl)benzonitrile(873056-29-2)
• EPA Substance Registry System: 5-amino-2-(tert-butyl)benzonitrile(873056-29-2)

Safety Data

• Hazardous Substances Data: 873056-29-2(Hazardous Substances Data)

Upstream product

• 3282-56-2 4-tert-butylnitrobenzene 
• 6310-17-4 2-bromo-1-tert-butyl-4-nitrobenzene 
• 873056-28-1 2-(tert-butyl)-5-nitrobenzonitrile 

Downstream Products

• 1610416-92-6 2-(tert-butyl)-5-(methoxymethyl)benzonitrile 
• 1369886-14-5 5-bromo-2-(tert-butyl)benzonitrile 

Relevant articles and documents

Heterocyclic compound

The present invention relates to compound (I) or a salt thereof which has a ROR γ t inhibitory action. wherein each symbol is as defined in the specification.

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.